Promomed Financial Statements (PRMD)
|
|
|
|
Report date
|
|
|
28.06.2024 |
28.06.2024 |
28.06.2024 |
|
|
13.10.2024 |
|
Currency
|
|
|
RUB |
RUB |
RUB |
RUB |
|
RUB |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
Presentation URL
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
13.2 |
13.5 |
15.8 |
21.1 |
|
17.1 |
|
Operating Income, bln rub |
|
|
4.62 |
5.35 |
5.60 |
|
|
5.90 |
|
EBITDA, bln rub |
? |
|
5.03 |
5.95 |
7.54 |
|
|
8.34 |
|
Net profit, bln rub |
? |
|
3.38 |
3.97 |
2.97 |
|
|
2.51 |
|
|
OCF, bln rub |
? |
|
2.04 |
2.96 |
-1.19 |
|
|
-4.01 |
|
CAPEX, bln rub |
? |
|
3.24 |
6.64 |
4.43 |
|
|
3.37 |
|
FCF, bln rub |
? |
|
-1.35 |
-3.68 |
-5.71 |
|
|
-6.70 |
|
Dividend payout, bln rub
|
|
|
|
|
|
|
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
|
|
|
0.0% |
|
0 |
|
Dividend payout ratio, %
|
|
|
0% |
0% |
0% |
|
|
0 |
|
|
OPEX, bln rub |
|
|
3.88 |
4.16 |
4.41 |
|
|
5.32 |
|
Cost of production, bln rub |
|
|
4.68 |
3.96 |
5.81 |
|
|
5.82 |
|
Amortization, bln rub |
|
|
0.4 |
0.6 |
1.0 |
|
|
1.1 |
|
Employment expenses, bln rub |
|
|
2.46 |
3.01 |
2.93 |
|
|
3.26 |
|
Interest expenses, bln rub |
|
|
0.400 |
0.740 |
1.59 |
|
|
2.47 |
|
|
Assets, bln rub |
|
|
16.3 |
25.9 |
34.8 |
|
|
38.6 |
|
Net Assets, bln rub |
? |
|
7.00 |
10.3 |
13.0 |
|
|
12.0 |
|
Debt, bln rub |
|
|
4.67 |
11.2 |
16.2 |
|
|
18.9 |
|
Cash, bln rub |
|
|
0.260 |
2.14 |
0.620 |
|
|
1.63 |
|
Net debt, bln rub |
|
|
4.41 |
9.03 |
15.6 |
0.00 |
|
17.2 |
|
|
Ordinary share price, rub |
|
|
|
|
|
355.3 |
|
404.0 |
|
Number of ordinary shares, mln |
|
|
|
|
200.0 |
200.0 |
|
200.0 |
|
|
Market cap, bln rub |
|
|
0.00 |
0.00 |
0.00 |
71.1 |
|
80.8 |
|
EV, bln rub |
? |
|
4.41 |
9.03 |
15.6 |
71.1 |
|
98.0 |
|
Book value, bln rub |
|
|
5.28 |
6.65 |
8.24 |
0.00 |
|
6.77 |
|
|
EPS, rub |
? |
|
|
|
14.9 |
0.00 |
|
12.6 |
|
FCF/share, rub |
|
|
|
|
-28.6 |
0.00 |
|
-33.5 |
|
BV/share, rub |
|
|
|
|
41.2 |
0.00 |
|
33.8 |
|
|
EBITDA margin, % |
? |
|
38.0% |
44.1% |
47.6% |
0.0% |
|
48.7% |
|
Net margin, % |
? |
|
25.5% |
29.5% |
18.8% |
0.0% |
|
14.7% |
|
FCF yield, % |
? |
|
|
|
|
0.0% |
|
-8.3% |
|
ROE, % |
? |
|
48.3% |
38.4% |
22.9% |
|
|
20.9% |
|
ROA, % |
? |
|
20.7% |
15.3% |
8.5% |
|
|
6.5% |
|
|
P/E |
? |
|
0.00 |
0.00 |
0.00 |
|
|
32.2 |
|
P/FCF |
|
|
0.00 |
0.00 |
0.00 |
|
|
-12.1 |
|
P/S |
? |
|
0.00 |
0.00 |
0.00 |
3.37 |
|
4.72 |
|
P/BV |
? |
|
0.00 |
0.00 |
0.00 |
|
|
11.9 |
|
EV/EBITDA |
? |
|
0.88 |
1.52 |
2.07 |
|
|
11.8 |
|
Debt/EBITDA |
|
|
0.88 |
1.52 |
2.07 |
|
|
2.07 |
|
|
Employees, people |
|
|
|
|
|
2 215 |
|
|
|
Labour productivity, mln rub/person/year |
|
|
|
|
|
9.53 |
|
|
|
Expenses per employee, thousand rub |
|
|
|
|
|
0.00 |
|
|
|
R&D/CAPEX, % |
|
|
0.00% |
0.00% |
0.00% |
|
|
0 |
|
|
CAPEX/Revenue, % |
|
|
24% |
49% |
28% |
0% |
|
20% |
|
| Promomed shareholders |
